Ascletis Advances Obesity Drug Candidate with Novel GLP-1/Amylin Combination
Event summary
- Ascletis Pharma has selected ASC30_39 FDC, a fixed-dose combination of GLP-1R agonist ASC30 and amylin receptor agonist ASC39, for clinical development targeting obesity.
- Preclinical dog studies indicate ASC30_39 FDC exhibits comparable pharmacokinetics to its monotherapies, with excellent oral bioavailability and a 12-hour half-life.
- ASC30, a Phase III-ready GLP-1R agonist, demonstrates a favorable GI profile, showing half the vomiting rate compared to orforglipron in non-head-to-head studies.
- Ascletis plans to submit an Investigational New Drug (IND) application to the FDA for ASC30_39 FDC in Q3 2026.
- The company claims ASC30_39 FDC represents the first publicly announced co-formulation of an oral GLP-1 and oral amylin.
The big picture
The obesity treatment market is experiencing rapid growth, driven by increasing prevalence and the emergence of effective therapies like GLP-1 receptor agonists. Ascletis’s approach of combining a GLP-1 agonist with an amylin agonist represents a novel strategy to potentially enhance efficacy and address limitations of existing treatments. However, the combination also introduces complexity in terms of safety and regulatory approval, and the company faces significant competition from established players and emerging therapies.
What we're watching
- Clinical Trial Design
- The success of ASC30_39 FDC will heavily depend on the design and execution of Phase 1 and subsequent clinical trials, particularly given the combination of two distinct mechanisms of action and the need to demonstrate synergistic efficacy and safety.
- Regulatory Pathway
- The FDA’s review of the IND submission and subsequent clinical trial data will be crucial; the novelty of the combination therapy could introduce unforeseen regulatory hurdles or require extensive safety data.
- Competitive Landscape
- The obesity treatment market is increasingly crowded, and Ascletis will need to demonstrate a clear advantage over existing and emerging therapies, including both GLP-1 receptor agonists and amylin mimetics, to achieve commercial success.
Related topics